155 related articles for article (PubMed ID: 16808678)
1. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
Yeom HY; Lee JH; Hong YJ; Seong GJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678
[TBL] [Abstract][Full Text] [Related]
2. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
Seong GJ; Lee YG; Lee JH; Lim SJ; Lee SC; Hong YJ; Kwon OW; Kim HB
Ophthalmic Surg Lasers; 2000; 31(4):308-14. PubMed ID: 10928668
[TBL] [Abstract][Full Text] [Related]
3. Use of topical brimonidine to prevent intraocular pressure elevations following Nd:YAG-laser posterior capsulotomy.
Gartaganis SP; Mela EK; Katsimpris JM; Petropoulos JK; Karamanos NK; Koliopoulos JX
Ophthalmic Surg Lasers; 1999; 30(8):647-52. PubMed ID: 10507567
[TBL] [Abstract][Full Text] [Related]
4. Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy.
Artunay O; Yuzbasioglu E; Unal M; Rasier R; Sengul A; Bahcecioglu H
J Ocul Pharmacol Ther; 2010 Oct; 26(5):513-7. PubMed ID: 20874499
[TBL] [Abstract][Full Text] [Related]
5. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Chevrier RL; Assalian A; Duperré J; Lesk MR
Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
[TBL] [Abstract][Full Text] [Related]
6. Fixed combination brimonidine-timolol versus brimonidine for treatment of intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
Öner V; Alakuş MF; Taş M; Türkyılmaz K; Işcan Y
J Ocul Pharmacol Ther; 2012 Dec; 28(6):576-80. PubMed ID: 22809091
[TBL] [Abstract][Full Text] [Related]
7. Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
Unal M; Yücel I; Akar Y
J Cataract Refract Surg; 2006 Sep; 32(9):1499-502. PubMed ID: 16931262
[TBL] [Abstract][Full Text] [Related]
8. The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy.
Elmi Sadr N; Saber E; Paknazar F
Clin Exp Optom; 2022 Nov; 105(8):813-816. PubMed ID: 34753412
[TBL] [Abstract][Full Text] [Related]
9. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic use of timolol maleate to prevent intraocular pressure elevation after Nd-YAG laser posterior capsulotomy.
Cai JP; Cheng JW; Wei RL; Ma XY; Jiang F; Zhu H; Li Y
Int Ophthalmol; 2008 Feb; 28(1):19-22. PubMed ID: 17585375
[TBL] [Abstract][Full Text] [Related]
11. Topical 2.0% dorzolamide vs oral acetazolamide for prevention of intraocular pressure rise after neodymium:YAG laser posterior capsulotomy.
Ladas ID; Baltatzis S; Panagiotidis D; Zafirakis P; Kokolakis SN; Theodossiadis GP
Arch Ophthalmol; 1997 Oct; 115(10):1241-4. PubMed ID: 9338667
[TBL] [Abstract][Full Text] [Related]
12. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
13. Levobunolol 0.5% and timolol 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
Rakofsky S; Koch DD; Faulkner JD; Terry SA; Mandell AI; Gross RL; Kelley EP; Iacono TL; Lue J
J Cataract Refract Surg; 1997 Sep; 23(7):1075-80. PubMed ID: 9379380
[TBL] [Abstract][Full Text] [Related]
14. The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
Simsek S; Ertürk H; Demirok A; Cinal A; Yasar T; Karadenizli C
Eur J Ophthalmol; 1998; 8(3):167-72. PubMed ID: 9793771
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of topic ocular hipotensive agents after posterior capsulotomy].
Minello AA; Prata Junior JA; Mello PA
Arq Bras Oftalmol; 2008; 71(5):706-10. PubMed ID: 19039468
[TBL] [Abstract][Full Text] [Related]
16. Long-term elevation of intraocular pressure after neodymium: YAG laser posterior capsulotomy.
Jahn CE; Emke M
Ophthalmologica; 1996; 210(2):85-9. PubMed ID: 9148259
[TBL] [Abstract][Full Text] [Related]
17. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
18. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Cantor LB; Safyan E; Liu CC; Batoosingh AL
Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052
[TBL] [Abstract][Full Text] [Related]
19. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
[TBL] [Abstract][Full Text] [Related]
20. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
